Scleroderma Therapeutics Market to Reach USD 4.49 Billion by 2035; Rising Focus on Targeted Therapies and Advancements in Autoimmune Disease Research Driving Market Growth ...

Growing Burden of Autoimmune Disorders, Expanding Biologic Pipeline, and Increasing Orphan Drug Support Accelerate Market Expansion.Austin, United States, March 19, 2026 (GLOBE NEWSWIRE) -- ...
Healio

FDA grants fast track designation to nipocalimab for adults with lupus

The FDA has granted fast track designation to the anti-FcRn agent nipocalimab for the treatment of adults with systemic lupus ...
The Lancet

Persisting CD19.CAR-T cells in combination with nintedanib: clinical response in a patient with systemic sclerosis-associated pulmonary fibrosis after 2 years

aDepartment of Hematology, Oncology and Rheumatology, Internal Medicine V, University Hospital Heidelberg, Heidelberg 69120, Germany bDepartment of Rheumatology, University Hospital Düsseldorf, ...

aTyr Pharma, Inc.: aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update

Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT study and determine the path forward for efzofitimod in pulmonary sarcoidosis. Phase 2 EFZO-CONNE ...
ascopubs.org

Emerging Systemic Treatment Perspectives on Brain Metastases: Moving Toward a Better Outlook for Patients

Emerging multiomic profiling is providing insights into the unique molecular features of brain metastases and potential targetable pathways. Molecular analysis of metastases, whenever possible, should ...